This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
A fungus devastating frogs and toads on nearly every continent may have an Achilles heel. Scientists have discovered a virus that infects the fungus, and that could be engineered to save the amphibians.
The startup claims to have a more efficient way to develop biologic drugs that treat disease by turning on cellular pathways, rather than blocking them.
A new study is among the first of its kind to separate activity relating to emotion generation from emotion regulation in the human brain. The findings provide new insights that could help inform therapeutic treatments regarding mental health and drug addiction.
The buyout continues a surge in M&A for developers of antibody-drug conjugates and gives Genmab a potential competitor to a medicine AbbVie recently purchased in a multibillion-dollar acquisition.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Oruka Therapeutics is the third startup from Paragon to go public since last year, and the second to do so by combining with another biotech.
176
176
Signup to get articles personalized to your interests!
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Can you tell us about your journey in the field of STEM and the challenges you encountered along the way? Everything started in school with an experiment on isolating DNA from bananas. Making a little tangle of DNA visible to the eye and understanding that this is the basis of complex organisms, which might be altered in disease, was the defining moment for my future path in life sciences.
The present review explores the intricate relationship between autophagy and proteostasis in the pathogenesis of neurodegenerative diseases along with the therapeutic interventions to mitigate the same. Abstract Neurodegenerative disorders are devastating disorders characterized by gradual loss of neurons and cognition or mobility impairment. The common pathological features of these diseases are associated with the accumulation of misfolded or aggregation of proteins.
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Researchers have developed a programmable meta-fluid with tunable springiness, optical properties, viscosity and even the ability to transition between a Newtonian and non-Newtonian fluid. The first-of-its-kind meta-fluid uses a suspension of small, elastomer spheres -- between 50 to 500 microns -- that buckle under pressure, radically changing the characteristics of the fluid.
By: Sue Batchelor, Executive Director, Oncology Project Management Radiopharmaceuticals represent a cutting-edge frontier in oncology treatment, offering the promise of highly targeted therapy with the potential to revolutionize cancer care. As with other targeted therapies, radiopharmaceutical development requires unique and specialized strategies to ensure successful execution.
Thank you to Charlotta Gauffin, Chief Scientific Officer at Dicot, for joining us for our recent webinar, “The Road to First-in-Human Trials: Insights from a Real-World Example.” Thoughtfully and carefully planned nonclinical studies help pave a smooth path toward first-in-human Phase 1 clinical trials. This involves a collaboration between all areas of nonclinical development, including CMC, toxicology, pharmacology, DPMK, and so on, and keeping in mind early a plan that all stakeholders agree
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
A team of astronomers has used NASA's James Webb Space Telescope to survey the starburst galaxy Messier 82 (M82). Located 12 million light-years away in the constellation Ursa Major, this galaxy is relatively compact in size but hosts a frenzy of star formation activity. For comparison, M82 is sprouting new stars 10 times faster than the Milky Way galaxy.
March was Women’s History Month and this year’s theme was “Women Who Advocate for Equity, Diversity and Inclusion.” This theme urged us to think about the diversity of U.S. women workers and how NIOSH is addressing health equity. Health equity is the state in which everyone has a fair and just opportunity to attain their highest level of health.[1] Occupational health inequities [2] can be influenced by exclusion and discrimination based on factors such as gender, socioeconomic position, and rac
New research makes a case study of Yellowstone National Park -- calculating surplus carbon that visitors from across the world add to the atmosphere each year as a direct result of a park visit.
Mini-Organs, Major Breakthroughs: How Hub Organoids Are Accelerating Oncology Drug Development dwunderlin Wed, 04/03/2024 - 17:28 Tue, 05/14/2024 - 09:30 Resource Type Webinar Dr. Sylvia F. Boj Duration 60 Minutes Patient-derived organoids are viewed as the gold standard in bridging the gap between the lab and the clinic. Advancements in HUB Organoid Technology, using patient material to generate “mini-organs” in a dish, have revolutionized in vitro predictivity over conventional 2D cell culture
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
One of the most fundamental interactions in physics is that of electrons and light. In an experiment, scientists have now managed to observe what is known as the Kapitza-Dirac effect for the first time in full temporal resolution. This effect was first postulated over 90 years ago, but only now are its finest details coming to light.
This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: Drug Channel Implications of the Inflation Reduction Act. The 2024 formularies described below should boost biosimilar adoption. As a new Biosimilar Council report shows , Humira retained 99% of market share in late 2023, despite being more expensive than its biosimilars.
In 2022, ICH Q14 officially introduced the enhanced approach 1 in analytical development as an alternative path to the minimal approach, the benefits of which are worth exploring further. Analytical data is essential in demonstrating the safety and quality of pharmaceutical products and therefore the data should be reliable. A prerequisite for data reliability is a robust and fit-for-purpose analytical method that performs consistently within predefined criteria and per the established performan
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.
Analytical Target Profile The analytical target profile (ATP) concept was first introduced in the ICH Q14 1 Guideline in 2022. This guideline, which compliments the ICH Q2 2 Guideline, describes science and risk-based approaches for developing and maintaining analytical procedures suitable for the evaluation of the quality of drug substances and drug products.
There are many options for clinical trial patient recruitment — digital advertising, in-person campaigns, and doctor’s office flyers are just a few. However, regardless of which avenue a study uses to find eligible individuals, there are a few basic tips that can help create effective outreach.
In the latest episode of “What If, So What?” host Jim Hertzfeld invites Eisaiah Engel, author of “ Innovation Casino ,” to dive deep into the essence of innovation in today’s business landscape. Engel shares his unique perspective on tackling innovation challenges across the spectrum as he and Jim explore the critical role of innovation in achieving differentiated, premium branding and generating alpha returns.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content